Vertex chose the right target in Nav1.8. Does it have the right commercial strategy?
Vertex’s Paul Negulescu discusses why Vertex picked Nav1.8 and where suzetrigine could fit in the pain treatment paradigm
Vertex is reaping the benefits of investing in a peripherally active pain target others ignored, with detailed Phase III data affirming suzetrigine’s potential as a long-awaited, safe and effective non-opioid pain therapy. The question now is whether the company can execute a launch strategy as effective as its clinical approach.
The company is positioning the Nav1.8 inhibitor as a treatment for post-surgical pain that can be used when NSAIDs or acetaminophen aren’t enough, but before turning to opioids. ...
BCIQ Company Profiles
BCIQ Target Profiles
Sodium voltage-gated channel alpha subunit 10 (Nav1.8) (PN3) (SCN10A)